Financial Performance - Fiscal Year 2024 - Sales increased by 6.2% to $147.658 billion[13] - Adjusted operating income decreased by 32.2% to $2.624 billion[13] - GAAP net loss was $8.636 billion, compared to a net loss of $3.080 billion in FY23[13] - Adjusted EPS decreased by 27.6% to $2.88[13] Financial Performance - Fourth Quarter 2024 - Sales increased by 6.0% to $37.547 billion[11] - Adjusted operating income decreased by 37.9% to $424 million[11] - GAAP net loss was $3.005 billion, compared to a net loss of $180 million in 4Q23[11] - Adjusted EPS decreased by 41.0% to $0.39[11] U.S. Retail Pharmacy - Fourth Quarter 2024 - Sales increased by 6.5% to $29.470 billion[14] - Adjusted operating income decreased by 60.4% to $220 million[14] - Comparable pharmacy sales increased by 11.7% primarily due to brand inflation and mix impacts[15] - Comparable scripts increased by 2.5%, and excluding immunizations, comparable scripts increased by 2.6%[15] U.S. Retail - Fourth Quarter 2024 - Total retail sales decreased by 3.5%[17] - Comparable retail sales decreased by 1.7%, reflecting a challenging retail environment and continued channel shift[17] International - Fourth Quarter 2024 - Sales increased by 3.7% to $5.971 billion, driven by Germany wholesale and Boots UK[19] - Adjusted operating income decreased by 10.6% to $231 million, mainly due to lapping real estate gains in the year-ago period[19] U.S. Healthcare - Fourth Quarter 2024 - Sales were $2.1 billion, led by VillageMD ($1.5 billion), CareCentrix ($0.4 billion), and Shields ($0.2 billion)[22] - Sales growth was +7%, led by VillageMD +7% and Shields +28%[22] - Adjusted EBITDA improved by $94 million compared to 4Q23, driven by cost savings at VillageMD and growth at Shields[22] FY25 Guidance - Adjusted EPS is expected to be between $1.40 and $1.80[27] - The company expects to close approximately 1,200 locations over the next three years, with approximately 500 in FY25[29] - The company expects sales between $147.0 and $151.0 billion[30]
Walgreens Boots Alliance(WBA) - 2024 Q4 - Earnings Call Presentation